Supercharged immune cells take on Hard-to-Treat cancers

NCT ID NCT07349160

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to better fight cancer. The study will enroll 36 participants and primarily look at safety, while also checking if the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metabolically armed tumor-infiltrating lymphocytes (Meta10-TIL cells)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 36 participants, so it is too soon to know if it will be safe or effective. The treatment involves infusing modified immune cells, which may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.